Emergent BioSolutions Inc.

Emergent BioSolutions announced a significant organizational restructuring plan, including a reduction of approximately 93 employees, elimination of 21 vacant positions, and closure of wet laboratories, expected to yield $40 million in annualized savings. Concurrently, the company reported Q2 2026 total revenues of $234.3 million (up 66%) but a net loss of $180.2 million due to a $191.3 million non-cash impairment charge on its NARCAN® asset group. The Chief Medical Officer, Head of R&D, Simon Lowry, will depart, and Stephanie Duatschek will assume the role of Executive Vice President, Chief Growth Officer.

Emergent BioSolutions underscored the growing importance of biological threat preparedness amidst an evolving security environment, citing risks from AI, synthetic biology, and geopolitical conflicts. The company highlighted its 25 years of partnering with governments to address potential bioterrorism threats and ensure robust response capabilities. Emergent also referenced a new NEJM Evidence study reinforcing the importance of its CYFENDUS® vaccine for anthrax post-exposure prophylaxis, reaffirming its commitment to collaborating on safeguards against emerging biological threats.

Emergent BioSolutions reported Q2 2026 total revenues of $234.3 million, a 66% increase year-over-year, significantly exceeding guidance. However, the company posted a net loss of $180.2 million, largely due to a $191.3 million non-cash impairment charge related to its NARCAN® asset group. Adjusted net income and adjusted EBITDA showed strong improvements, rising 134% and 192% respectively. Concurrently, Emergent announced an organizational restructuring, including a reduction of approximately 90 roles, aiming for $40 million in annualized savings, and revised its full-year 2026 financial forecast downwards.

Emergent BioSolutions Inc. announced it will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time. The purpose of the call is to discuss the company's financial results for the second quarter of 2026. Interested parties can access the call live via webcast on the company's Investors page or register in advance for telephone participation.

Emergent BioSolutions announced a $52.7 million contract modification from the U.S. Department of Health and Human Services' ASPR. The contract is for the supply of ACAM2000® (Smallpox and Mpox Vaccine) and related items to support national preparedness. Deliveries are anticipated to begin this month. This award reinforces Emergent's role in biodefense and follows recent international approvals for ACAM2000® in Saudi Arabia and Singapore.

Emergent BioSolutions is partnering with Victoria's Voice Foundation for National Naloxone Awareness Day on June 6th to combat the ongoing opioid epidemic. The collaboration supports the "Shine. Wear. Share. Care." campaign, which promotes education and preparedness by distributing purple light bulbs, promotional items, social media engagement, and NARCAN® Nasal Spray. Emergent is committed to expanding access to NARCAN® Nasal Spray, including through a new carrying case and the "Ready to Rescue" initiative with spokesperson Zac Clark. The company is a leading U.S. supplier of nasal naloxone, offering both OTC NARCAN® and prescription KLOXXADO®.

Emergent BioSolutions Inc. announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the U.S. Department of Health and Human Services (HHS). This modification to an existing 10-year contract ensures the continued supply of BAT® (Botulism Antitoxin Heptavalent), an antitoxin used for treating symptomatic botulism. The company highlighted its ongoing support for U.S. biodefense and preparedness priorities, leveraging its specialized capabilities and North American supply chain.

Emergent BioSolutions Inc. announced that its senior management team will participate in four upcoming investor conferences in May and June. These include the Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. The company will deliver presentations at the Jefferies and Goldman Sachs Global Healthcare conferences, with webcasts available for both.

Emergent BioSolutions announced that the Saudi Food and Drug Authority (SFDA) has approved ACAM2000® vaccine for the prevention of smallpox and mpox in high-risk individuals. This marks the first Emergent product licensed by the SFDA, signaling the company's intent to expand collaborations in the Gulf region. The approval follows a recent expanded indication approval by Singapore's Health Sciences Authority for ACAM2000® to include mpox prevention. The vaccine addresses global health threats, with over 137,000 mpox cases and 300 deaths reported globally since 2022.

Emergent BioSolutions Inc. reported Q1 2026 total revenues of $156.1 million, exceeding the high end of its guidance range, with net income of $6.8 million and adjusted EBITDA of $35.6 million. The company announced a debt refinancing to increase strategic flexibility and reduce interest expense, alongside securing new strategic manufacturing partnerships with Substipharm Biologics and SAB Biotherapeutics. Emergent also maintained market share for NARCAN® Nasal Spray and secured over $200 million in new government contracts for medical countermeasures, while revising its full-year 2026 adjusted net income and adjusted EBITDA forecasts upwards.